Akatinol memantine in patients with vascular cognitive disorders

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 110, Issue 12, 2010, Pages 37-40

  Gudkova, A A ^a   Sorokina, I B ^a   Yakovlev, A A ^a   Gulayeva, N V ^a   Guekht, A B ^a  

^a NONE

Author keywords

Akatinol memantine; Vascular dementia; Vascular moderate cognitive impairment

Indexed keywords

MEMANTINE; AMINO ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ARTICLE; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DYNAMICS; EVALUATION; HUMAN; NEUROPSYCHOLOGICAL TEST; RANDOMIZATION; SPEECH; TREATMENT DURATION; VISION; VISUAL MEMORY; AGED; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; MALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; OPEN STUDY; VASCULAR COGNITIVE DISORDER;

AGED; AGED, 80 AND OVER; CEREBROVASCULAR DISORDERS; COGNITION; COGNITION DISORDERS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 79953289537     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Russian source
6. Russian source
7. Russian source
8. Russian source
9. Russian source
10. Russian source
11. Russian source
12. Russian source
13. Russian source
14. Russian source
15. Russian source
16. Russian source
17. Russian source
18. Russian source
19. Russian source
20. Russian source
21. Balazs R. Trophic effect of glutamate. Curr Top Med Chem 2006; 6: 961-968.
22. Carrol R.C., Zukin R.S. NMDA-receptor trafficking and targeting; implications for synaptic tpansmission and plasticity. Trends Neurosci 2002; 25: 571-577.
23. Debette S., Beiser A., DeCarli C. et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 2010; 41: 4: 574.
24. De Haan E.H., Nys G.M., Van Zandvoort M.J.V. Cognitive function following stroke and vascular cognitive impairment. Opin Neurol 2006; 19: 559-564.
25. DiCarlo A., Baldereschi M., Amaducci L. et al. Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging. J Am Ger Soc 2000; 48: 775-782.
26. Dingledine R., Borges K., Bowie D., Traynelis S. The glutamate receptor ion channels. Pharmacol Rev 1994; 51: 7-61.
27. Ferguson J.M., Shingleton R.N. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 2007; 30: 3: 136-144.
28. Folstein M., Folstein S., McHugh P. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1991; 12: 189-190.
29. Gelinas I., Gautier L. et al. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999; 53: 471-481.
30. Grant S.G. Synapse signaling complexes and networks; machines underlying cognition. Bioessays 2003; 25: 1229-1235.
31. Hachinski V.C., Iliff L.D., Zilkha E. et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632-637.
32. Hachinski V., Bowler J.V. Vascular dementia: diagnostic criteria for research studies. Neurology 1993; 43: 2159-2160.
33. Hamilton N. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1960; 6: 278-296.
34. Khodorov B. Glutamate-induced deregulation of calcium home ostasis and mitochondrial dysfunction in mammalian central neurons. Prog Biophys Mol Biol 2004; 86: 279-351.
35. Kivipelto M., Helkala E.L., Hanninen T. et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001; 56: 1683-1689.
36. Leys D., Englund E., Erkinjuntti T. Vascular dementia. In: Evidence-based Dementia Practice. Ed. by N. Qizilbash et al. Oxford etc.: Blackwell Science 2002; 260-287.
37. Lyketsos C.G., Sheppard J.M., Rabins P.V. Dementia in elderly persons in general hospital. Am J Psychiat 2000; 157: 704-707.
38. Orgogozo J.M., Rigaud A.S., Stoffler A. et al. Efficacy and safety of Memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM-300). Stroke 2002; 33: 7: 1834-1839.
39. Pantoni L., Poggesi A., Inzitari D. Cognitive decline and dementia related to cerebrovascular diseases: some evidence and concepts. Cerebrovasc Dis 2009; 27: Suppl 1: 191-196.
40. Rocca W.A., Knopman D.S. Prevalence and incidence of vascular dementia. In: Vascular Cognitive Impairment: Preventable Dementia. Ed. by J.V. Bowler.
41. Roman G.C. et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Work Group. Neurology 1993; 43: 250-260.
42. Roman G.C. Clinical Forms of Vascular Dementia. In: Vascular Dementia: Cerebrovascular Mechanisms and Clinical Management. Ed. by R.H. Paul et al. Totowa: Humana Press 2005; 7-21.
43. Rosen W.G., Mohs R.S., Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiat 1984; 141: 1356-1364.